Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514838 | 0.88 | PTGS1 (0.38) | PTGS1PTGS2CA2SIRT1 | |
| SCHEMBL1964598 | 0.81 | PTGS1 (0.39) | PTGS1PTGS2CA2SLC22A12 | |
| SCHEMBL514430 | 0.79 | CA2 (0.39) | PTGS1PTGS2CA2 | |
| SCHEMBL24370477 | 0.78 | PTGS1 (0.42) | PTGS1PTGS2CA2SLC22A12 | |
| SCHEMBL4918542 | 0.76 | PTGS1 (0.40) | PTGS1PTGS2CA2SLC22A12 | |
| SCHEMBL4919572 | 0.75 | PTGS1 (0.41) | PTGS1PTGS2CA2SLC22A12 | |
| SCHEMBL1966561 | 0.75 | PTGS1 (0.39) | PTGS1PTGS2CA2MAPT | |
| SCHEMBL513334 | 0.74 | CA2 (0.39) | PTGS1PTGS2CA2 | |
| SCHEMBL2582217 | 0.74 | PTGS1 (0.39) | PTGS1PTGS2CA2SLC22A12 | |
| SCHEMBL1964848 | 0.74 | L3MBTL1 (0.47) | PTGS1PTGS2CA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | PTGS1 3479/4885PTGS2 4244/4885CA2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.